Pediatric patients with immune-mediated diseases on immunosuppressants have low risk of severe COVID-19 and no increase in flare rate after SARS CoV-2 exposure

J Infect. 2022 Sep;85(3):e62-e65. doi: 10.1016/j.jinf.2022.06.012. Epub 2022 Jun 18.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • COVID-19*
  • Child
  • Humans
  • Immunosuppressive Agents / adverse effects
  • SARS-CoV-2*

Substances

  • Immunosuppressive Agents